Search company, investor...

Founded Year



Dead | Dead

Total Raised


About On-Q-ity

On-Q-ity is a life sciences company focused on circulating tumor cell (CTC) capture and characterization. The company is developing products and services for clinical researchers and physicians that will enhance decision-making across multiple cancer types. On-Q-ity's goals is to increase the success of oncology drug development, improve patient treatment outcomes and increase survival rates.

Headquarters Location

610 Lincoln Street 3rd Floor, North Building

Waltham, Massachusetts, 02451,

United States




Research containing On-Q-ity

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned On-Q-ity in 1 CB Insights research brief, most recently on Dec 12, 2023.

On-Q-ity Patents

On-Q-ity has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics



Cell biology, Clusters of differentiation, Biotechnology, Transcription factors, Analytical chemistry


Application Date


Grant Date


Related Topics

Cell biology, Clusters of differentiation, Biotechnology, Transcription factors, Analytical chemistry



Latest On-Q-ity News

Dx startup On-Q-ity shuts down

Feb 2, 2018

Apr 12, 2013 7:47am On-Q-ity, a cancer diagnostics startup focused on circulating tumor cells, is officially defunct. Bruce Booth, a partner at On-Q-ity investor Atlas Ventures, confirms the Waltham, MA-based company's demise in his blog "Life Sci VC" where he said the final asset sale is wrapping up, after the board decided in November to shut things down. His account of what happened is unusually candid and gives a window into the risks involved in diagnostics development despite promising technology. Booth writes that "diagnostics aren't for the faint of heart," and that the sector is "a very tough business that faces many of the risks and costs of drug R&D but without the upside." And On-Q-ity, hit with unexpected problems, may have just been ahead of its time. As Booth describes in his blog, On-Q-ity launched with some fanfare in 2009 through the merger of VC-backed diagnostics firms Cellective Dx and DNA Repair Inc., backed by a $26 million Series A led by Mohr Davidow Ventures and also including Bessemer, Physic and Atlas. On-Q-ity founder Mara Aspinall (now head of Roche's Ventana Medical Systems), brought with her a distinguished track record having run Genzyme for years. Other principals brought solid backgrounds from Myriad Genetics, Genomic Health, Dana Farber Cancer Institute and elsewhere, Booth recalled, based on notes he made in support of the company's 2009 Series A. The technology itself also held promise, which was designed to allow clinicians to grab circulating tumor cells from a patient's blood and then count them and detail the type of cancer, enabling, in theory, personalized treatment. Separately, On-Q-ity also was developing DNA repair pathway tissue-based biomarkers to predict drug response for breast and lung cancer. But, as Booth describes, the biomarker research ended up generating disappointing results in an early trial and two more larger tests, sucking up a lot of the Series A financing. A refocus on the circulating tumor cell (CTC) diagnostic program ran into unexpected development problems, leading to the severing of a LabCorp partnership. Then came massive management changes. Booth explains that the company's team made enormous R&D progress and raised a small Series B to help keep things going. But a search for a strategic partner/acquirer to continue work on the circulating tumor cell technology didn't succeed, and the principals decided to wind the company down. So what went wrong? Booth argues in his blog that merging two promising but as yet "cash burning businesses" into a single company ended up being quite challenging, noting that "crashing two Fords together doesn't make a Porsche." He also said that investors should have tranched the funding into stages, to allow for the technology to be validated with smaller financing before rewarding it with more funds. Management instability didn't help, he said. But ultimately, On-Q-ity may have simply been ahead of its time, particularly with CTC diagnostics, launching before outside investors or potential partners were willing to ride out its development. Cedars-Sinai Medical Center/UCLA are making progress with a NanoVelcro Chip that enables the use of CTCs for diagnostics. Epic Sciences also raised a $13 million Series B round last fall to advance its molecular diagnostic test that relies on circulating tumor cells, just to name two of many CTC diagnostic development efforts now gaining traction. - read Booth's full blog entry About the Author

On-Q-ity Frequently Asked Questions (FAQ)

  • When was On-Q-ity founded?

    On-Q-ity was founded in 2009.

  • Where is On-Q-ity's headquarters?

    On-Q-ity's headquarters is located at 610 Lincoln Street, Waltham.

  • What is On-Q-ity's latest funding round?

    On-Q-ity's latest funding round is Dead.

  • How much did On-Q-ity raise?

    On-Q-ity raised a total of $31.97M.

  • Who are the investors of On-Q-ity?

    Investors of On-Q-ity include Physic Ventures, Mohr Davidow Ventures, Atlas Venture, Qualifying Therapeutic Discovery Project, Bessemer Venture Partners and 3 more.

  • Who are On-Q-ity's competitors?

    Competitors of On-Q-ity include CivaTech Oncology, AltheaDx, Decipher Biosciences, Exagen, 20/20 GeneSystems and 7 more.


Compare On-Q-ity to Competitors

CivaTech Oncology Logo
CivaTech Oncology

Civatech Oncology is a medical device company focused on the development of polymer-based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for the encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy. CivaTech Oncology was founded in 2006 and is based in Durham, North Carolina.


The company's primary goals are to eliminate unnecessary breast surgeries, find the breast cancers that are often missed, facilitate the therapy delivery process, and save the company's healthcare system $2.3 billion annually. n


NeoDiagnostix is a cancer diagnostics company with a focus on women's health, specifically in the domain of cervical cancer detection. The company's main offering is the Cervical DNA Dtex Test, which identifies irreversible DNA damage to cervical cells as an indicator of potential cancer. This diagnostic tool is primarily utilized by healthcare providers in the medical sector. It is based in Rockville, Maryland.


Predict to Prevent  Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development  of  presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention


CS-Keys is a company that operates in the digital gaming industry, focusing on the trading of game keys. The company's main service involves the buying and selling of keys for the games CS:GO and TF2, which are used to unlock in-game items. The company primarily serves the online gaming community. It was founded in 2006 and is based in Indianapolis, Indiana.


Glycominds is a diagnostics company focused on developing and commercializing biomarkers for autoimmune and chronic inflammatory diseases, particularly within the gastrointestinal sector. The company offers non-invasive blood tests for the detection, diagnosis, prognosis, and therapy monitoring of gastrointestinal diseases such as Celiac Disease and Inflammatory Bowel Diseases, including Crohn's Disease and Ulcerative Colitis. Glycominds' products serve as an alternative to traditional invasive diagnostic techniques, providing accurate and cost-effective solutions for healthcare providers. It is based in Redwood City, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.